Drug Profile
Research programme: protein target therapeutics - Celgene/FORMA Therapeutics
Alternative Names: Epigenetic compounds - Celgene/FORMA Therapeutics; Epigenetic compounds - FORMA Therapeutics/CelgeneLatest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator FORMA Therapeutics
- Class Antineoplastics
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Non-alcoholic steatohepatitis
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 28 Oct 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb